Abivax S.A. Form 6-K Summary: Six Months Ended June 30, 2024
Business Context and Reporting Period
This Form 6-K reports the unaudited financial results for Abivax S.A., a clinical-stage biotechnology company, for the six months ended June 30, 2024. The company focuses on developing therapeutics for chronic inflammatory diseases, with its lead candidate, obefazimod, currently in Phase 3 trials for ulcerative colitis (UC) and preparing for Phase 2b trials in Crohn's disease (CD). The financial statements are prepared in accordance with IFRS as adopted by the EU.
Key Financial Metrics
| Metric (in thousands of EUR) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Total Operating Income | 6,815 | 2,255 |
| Total Operating Expenses | (86,811) | (39,535) |
| Operating Loss | (79,997) | (37,280) |
| Net Loss | (81,638) | (51,953) |
| Cash and Cash Equivalents (End of Period) | 222,317 | 114,381 |
| Net Cash Used in Operating Activities | (85,175) | (27,599) |
| Net Cash Provided by Financing Activities | 40,322 | 116,742 |
Debt and Liquidity: As of June 30, 2024, total financial debt obligations were approximately €127.5 million, including senior secured non-convertible bonds from Kreos/Claret and convertible notes from Heights. The company holds €222.3 million in cash and cash equivalents.
Material Changes vs. Prior Period
- Revenue/Income: Total operating income increased 202% to €6.8 million, driven primarily by a €4.1 million increase in subsidies. This resulted from Bpifrance waiving 60% of remaining conditional advances and accrued interest on the terminated RNP-VIR and CARENA projects.
- Expenses: Total operating expenses rose 120% to €86.8 million.
- R&D Expenses: Increased 98% to €64.7 million, largely due to the progression of Phase 3 clinical trials for obefazimod in UC (€25.6 million increase) and expanded R&D headcount.
- G&A Expenses: Increased 165% to €17.9 million, driven by personnel costs (including new equity awards) and costs associated with operating as a dual-listed public company.
- Sales & Marketing: Increased significantly to €4.2 million from €0.2 million, reflecting market research for future U.S. commercialization.
- Financial Results: Net loss increased 57% to €81.6 million. However, the net financial loss improved significantly (decreased by 89%) to €1.6 million compared to €14.7 million in the prior year, due to higher interest income and foreign exchange gains offsetting interest expenses.
Guidance, Outlook, and Risks
- Clinical Outlook: The ABTECT Phase 3 trial for UC surpassed the 600-patient enrollment milestone in August 2024, with top-line induction results expected in early Q2 2025. The Phase 2b trial for Crohn's disease is expected to initiate in September 2024.
- Liquidity Runway: Management expects to fund operations through Q4 2025 based on current cash of €222.3 million and expected Research Tax Credit (CIR) reimbursements of €4.5 million in late 2024. This runway covers the announcement of top-line Phase 3 UC data.
- Management Changes: In July 2024, Sylvie Grégoire was appointed Chair of the Board. Fabio Cataldi was appointed Chief Medical Officer, and David Zhang joined as Chief Strategy Officer. Several executives, including the former CMO and CCO, resigned.
- Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for additional financing. Specific risks include the impact of geopolitical conflicts (Russia-Ukraine, Israel-Hamas) on supply chains and clinical sites, though the company has excluded Russia/Belarus from its Phase 3 program.
Key Facts for Investor Verification
- Cash Runway: Verify the assumption that current cash plus expected CIR reimbursements will sustain operations through Q4 2025 without additional capital raises.
- Subsidy Recognition: Confirm the non-recurring nature of the €4.1 million subsidy income from Bpifrance related to project terminations.
- Debt Structure: Review the terms of the Kreos/Claret and Heights financings, specifically the Minimum Return Indemnifications (MRI) and conversion features that impact fair value accounting.
- Clinical Milestones: Monitor the timeline for the ABTECT Phase 3 induction data read-out (expected early Q2 2025) as a critical value inflection point.
- Expense Trajectory: Assess the sustainability of the 98% increase in R&D spend and 165% increase in G&A as the company scales toward commercialization.